Caner Ercan
Impact in
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Hepatology top 10%
- Liver physiology and pathology
Papers in
-
- RNA modifications and cancer 4
- Oncology 9
- Cancer-related Molecular Pathways 3
- Co-authors
- Salvatore Piscuoglio (18 shared papers)Mairene Coto‐Llerena (13 shared papers)Ravi Kiran Reddy Kalathur (3 shared papers)Gerhard Christofori (3 shared papers)David Buechel (2 shared papers)Fengyuan Tang (2 shared papers)Ruize Gao (2 shared papers)Michael T. Dill (1 shared paper)
- Journals
- Nature Communications (2 papers)Cancers (2 papers)Frontiers in Oncology (2 papers)Cancer Research (2 papers)Molecular Oncology (1 paper)
- Partner nations
- SwitzerlandItalyUnited States
In The Last Decade
Caner Ercan
22 papers receiving 897 citations
Caner Ercan's Hit Papers
Peers
Comparison fields: 5 of 74
- Cancer Research 373
- Hepatology 103
- Pulmonary and Respiratory Medicine 310
- Molecular Biology 536
- Oncology 175
Countries citing papers authored by Caner Ercan
This map shows the geographic impact of Caner Ercan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caner Ercan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caner Ercan more than expected).
Fields of papers citing papers by Caner Ercan
This network shows the impact of papers produced by Caner Ercan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caner Ercan. The network helps show where Caner Ercan may publish in the future.
Co-authors
The 25 scholars most cited alongside Caner Ercan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis Hit paper breakdown → | 2021 | 348 |
| 2 | Arginine reprograms metabolism in liver cancer via RBM39 Hit paper breakdown → | 2023 | 145 |
| 3 | 2022 | 88 | |
| 4 | Bipotent transitional liver progenitor cells contribute to liver regeneration Hit paper breakdown → | 2023 | 74 |
| 5 | 2020 | 63 | |
| 6 | 2021 | 46 | |
| 7 | 2021 | 28 | |
| 8 | 2022 | 17 | |
| 9 | 2022 | 14 | |
| 10 | 2021 | 14 | |
| 11 | 2020 | 12 | |
| 12 | 2022 | 11 | |
| 13 | 2021 | 10 | |
| 14 | 2021 | 7 | |
| 15 | 2024 | 7 | |
| 16 | 2022 | 7 | |
| 17 | 2024 | 4 | |
| 18 | 2021 | 4 | |
| 19 | 2023 | 2 | |
| 20 | 2024 | 2 |
About Caner Ercan
Caner Ercan is a scholar working on Molecular Biology, Oncology, Cancer Research, Hepatology and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 906 indexed citations. Recurring topics across this work include RNA modifications and cancer (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Hepatitis B Virus Studies (3 papers), Immune Cell Function and Interaction (3 papers), Cancer Genomics and Diagnostics (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Cancer-related Molecular Pathways (3 papers) and Cancer Research and Treatments (2 papers). The work is most often cited by research in Cancer Research (373 citations), Hepatology (103 citations), Pulmonary and Respiratory Medicine (310 citations), Molecular Biology (536 citations) and Oncology (175 citations). Caner Ercan has collaborated with scholars based in Switzerland, Italy and United States. Frequent co-authors include Salvatore Piscuoglio, Mairene Coto‐Llerena, Ravi Kiran Reddy Kalathur, Gerhard Christofori, David Buechel, Fengyuan Tang, Ruize Gao, Michael T. Dill, Shuang Song and Fernando D. Camargo. Their work appears in journals such as Nature Communications, Cancers, Frontiers in Oncology, Cancer Research and Molecular Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.